Caterina Giannini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8501422/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	13.9	2,582
2	Glioma Groups Based on 1p/19q, <i>IDH</i> , and <i>TERT</i> Promoter Mutations in Tumors. New England Journal of Medicine, 2015, 372, 2499-2508.	13.9	1,632
3	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	7.7	836
4	A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma. Cancer Research, 2006, 66, 9852-9861.	0.4	678
5	Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathologica, 2012, 123, 295-319.	3.9	525
6	Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncology, 2018, 20, 184-191.	0.6	443
7	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	2.1	363
8	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of <i>IDH</i> . Journal of Clinical Oncology, 2014, 32, 783-790.	0.8	356
9	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathologica, 2020, 139, 603-608.	3.9	344
10	Pleomorphic xanthoastrocytoma. Cancer, 1999, 85, 2033-2045.	2.0	312
11	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-Oncology, 2005, 7, 164-176.	0.6	296
12	cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathologica, 2018, 135, 639-642.	3.9	281
13	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	5.1	274
14	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathologica, 2017, 133, 1001-1016.	3.9	245
15	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Cliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	0.8	232
16	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	9.4	214
17	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	3.9	190
18	Pleomorphic Xanthoastrocytoma: Natural History and Longâ€Term Followâ€Up. Brain Pathology, 2015, 25, 575-586.	2.1	188

#	Article	IF	CITATIONS
19	Oligodendrogliomas: Reproducibility and Prognostic Value of Histologic Diagnosis and Grading. Journal of Neuropathology and Experimental Neurology, 2001, 60, 248-262.	0.9	186
20	A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nature Communications, 2018, 9, 2949.	5.8	183
21	Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence. Journal of Digital Imaging, 2017, 30, 469-476.	1.6	167
22	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	0.8	160
23	Cellular Proliferation in Pilocytic and Diffuse Astrocytomas. Journal of Neuropathology and Experimental Neurology, 1999, 58, 46-53.	0.9	156
24	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Annals of Neurology, 2016, 79, 437-447.	2.8	148
25	clMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathologica, 2018, 135, 481-484.	3.9	145
26	A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nature Genetics, 2012, 44, 1122-1125.	9.4	131
27	Primary central nervous system vasculitis: pathology and mechanisms. Acta Neuropathologica, 2012, 123, 759-772.	3.9	130
28	Recurrent noncoding U1ÂsnRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature, 2019, 574, 707-711.	13.7	129
29	Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. Acta Neuropathologica, 2016, 132, 149-151.	3.9	127
30	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology, 2015, 17, 1261-1269.	0.6	126
31	Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology, 2008, 18, 360-369.	2.1	125
32	Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. Clinical Cancer Research, 2020, 26, 1094-1104.	3.2	124
33	IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget, 2015, 6, 30295-30305.	0.8	113
34	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. JAMA Neurology, 2020, 77, 1420.	4.5	109
35	Immunophenotype of Pleomorphic Xanthoastrocytoma. American Journal of Surgical Pathology, 2002, 26, 479-485.	2.1	107
36	2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. Radiographics, 2017, 37, 2164-2180.	1.4	105

#	Article	IF	CITATIONS
37	A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1039-1054.	0.9	105
38	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	0.6	99
39	Management of diffuse low-grade gliomas in adults — use of molecular diagnostics. Nature Reviews Neurology, 2017, 13, 340-351.	4.9	95
40	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro-Oncology, 2018, 20, 546-556.	0.6	93
41	CNS Lymphoma. Journal of Neuropathology and Experimental Neurology, 2014, 73, 478-494.	0.9	92
42	Pleomorphic xanthoastrocytoma: what do we really know about it?. Cancer, 1999, 85, 2033-45.	2.0	91
43	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	3.9	86
44	Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. Journal of the National Cancer Institute, 2018, 110, 1123-1132.	3.0	83
45	Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. European Journal of Endocrinology, 2019, 180, 127-134.	1.9	80
46	Pleomorphic xanthoastrocytoma. , 1999, 85, 2033.		74
47	Intracranial myxoid mesenchymal tumors with <i>EWSR1</i> – <i>CREB</i> family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity?. Brain Pathology, 2018, 28, 183-191.	2.1	72
48	Recurrent copy number alterations in lowâ€grade and anaplastic pleomorphic xanthoastrocytoma with and without <i>BRAF</i> V600E mutation. Brain Pathology, 2018, 28, 172-182.	2.1	64
49	<i>NAB2-STAT6</i> Gene Fusion in Meningeal Hemangiopericytoma and Solitary Fibrous Tumor. Journal of Neuropathology and Experimental Neurology, 2016, 75, 263-271.	0.9	63
50	Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2016, 75, 44-52.	0.9	63
51	Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. American Journal of Neuroradiology, 2017, 38, 678-684.	1.2	63
52	Brain ischemic injury in COVIDâ€19â€infected patients: a series of 10 postâ€mortem cases. Brain Pathology, 2021, 31, 205-210.	2.1	61
53	CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro-Oncology, 2021, 23, 457-467.	0.6	58
54	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. Acta Neuropathologica, 2018, 136, 293-302.	3.9	56

#	Article	IF	CITATIONS
55	Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. Neurogenetics, 2001, 3, 159-162.	0.7	55
56	Revisiting Adjuvant Radiotherapy After Gross Total Resection of World Health Organization Grade II Meningioma. World Neurosurgery, 2017, 103, 655-663.	0.7	55
57	Alternative lengthening of telomeres, ATRX loss and H3â€K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. Brain Pathology, 2019, 29, 126-140.	2.1	54
58	Toward a better definition of focal cortical dysplasia: An iterative histopathological and genetic agreement trial. Epilepsia, 2021, 62, 1416-1428.	2.6	54
59	Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Acta Neuropathologica Communications, 2013, 1, 20.	2.4	52
60	Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. Acta Neuropathologica, 2018, 135, 299-301.	3.9	51
61	A phase 1 and randomized, placebo ontrolled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer, 2019, 125, 3790-3800.	2.0	51
62	Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. Journal of Neuropathology and Experimental Neurology, 2019, 78, 791-797.	0.9	50
63	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology, 2015, 84, 148-158.	1.5	49
64	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.	0.6	49
65	Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology, 2019, 61, 1327-1332.	1.1	48
66	WHO 2016 classification: changes and advancements in the diagnosis of miscellaneous primary <scp>CNS</scp> tumours. Neuropathology and Applied Neurobiology, 2018, 44, 163-171.	1.8	47
67	Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro-Oncology, 2019, 21, 1458-1469.	0.6	47
68	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	5.8	47
69	Interictal Scalp Electroencephalography and Intraoperative Electrocorticography in Magnetic Resonance Imaging–Negative Temporal Lobe Epilepsy Surgery. JAMA Neurology, 2014, 71, 702.	4.5	45
70	The impact of histopathology and NAB2–STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. Acta Neuropathologica, 2019, 137, 307-319.	3.9	44
71	Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup. American Journal of Surgical Pathology, 2018, 42, 506-511.	2.1	43
72	Choristoma of the Optic Nerve: Case Report. Neurosurgery, 2002, 50, 1125-1128.	0.6	39

#	Article	IF	CITATIONS
73	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
74	Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro-Oncology, 2021, 23, 2042-2053.	0.6	37
75	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. Acta Neuropathologica, 2020, 139, 277-286.	3.9	36
76	Histopathologic grading of adult medulloblastomas. Cancer, 2007, 109, 2557-2565.	2.0	34
77	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	3.9	34
78	Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?. Brain Pathology, 2021, 31, 20-32.	2.1	32
79	Mycophenolate mofetil in primary central nervous system vasculitis. Seminars in Arthritis and Rheumatism, 2015, 45, 55-59.	1.6	30
80	Gene Expression in Solitary Fibrous Tumors (SFTs) Correlates with Anatomic Localization and NAB2-STAT6 Gene Fusion Variants. American Journal of Pathology, 2021, 191, 602-617.	1.9	30
81	Long-term remission, relapses and maintenance therapy in adult primary central nervous system vasculitis: A single-center 35-year experience. Autoimmunity Reviews, 2020, 19, 102497.	2.5	29
82	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. Journal of Neuro-Oncology, 2015, 124, 413-420.	1.4	27
83	Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. Journal of Neuro-Oncology, 2018, 137, 583-591.	1.4	26
84	Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. Brain Pathology, 2016, 26, 206-214.	2.1	25
85	Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary, 2021, 24, 192-206.	1.6	25
86	Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. Modern Pathology, 2018, 31, 1787-1800.	2.9	24
87	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	3.3	24
88	Using germline variants to estimate glioma and subtype risks. Neuro-Oncology, 2019, 21, 451-461.	0.6	23
89	Epidemiology, natural history, and optimal management of neurohypophyseal germ cell tumors. Journal of Neurosurgery, 2020, , 1-9.	0.9	23
90	Primary central nervous system vasculitis associated with lymphoma. Neurology, 2018, 90, e847-e855.	1.5	22

#	Article	IF	CITATIONS
91	Globular Glial Tauopathy Presenting as Semantic Variant Primary Progressive Aphasia. JAMA Neurology, 2016, 73, 123.	4.5	21
92	Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, 068-074.	0.4	21
93	Sellar Region Atypical Teratoid/Rhabdoid Tumors in Adults: Clinicopathological Characterization of Five Cases and Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1115-1121.	0.9	21
94	Comparison on epidemiology, tumor location, histology, and prognosis of intracranial germ cell tumors between Mayo Clinic and Japanese consortium cohorts. Journal of Neurosurgery, 2021, 134, 446-456.	0.9	21
95	Primary central nervous system vasculitis mimicking brain tumor: Comprehensive analysis of 13 cases from a single institutional cohort of 191 cases. Journal of Autoimmunity, 2019, 97, 22-28.	3.0	20
96	Adult diffuse glioma GWAS by molecular subtype identifies variants in <i>D2HGDH</i> and <i>FAM20C</i> . Neuro-Oncology, 2020, 22, 1602-1613.	0.6	19
97	Novel Diagnostic Methods and Posttreatment Clinical Phenotypes Among Intracranial Germ Cell Tumors. Neurosurgery, 2020, 87, 563-572.	0.6	18
98	Subependymal giant cell astrocytoma in a genetically negative tuberous sclerosis complex adult: Case report. Clinical Neurology and Neurosurgery, 2016, 150, 177-180.	0.6	17
99	Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature. Autoimmunity Reviews, 2019, 18, 399-405.	2.5	17
100	Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance). Neuro-Oncology Practice, 2015, 2, 199-204.	1.0	16
101	Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. Neuro-Oncology Advances, 2020, 2, vdaa109.	0.4	15
102	Case-Based Review: newly diagnosed glioblastoma. Neuro-Oncology Practice, 2015, 2, 106-121.	1.0	13
103	Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation. Journal of Neuropathology and Experimental Neurology, 2021, 80, 821-829.	0.9	13
104	Maintaining Clinical Tissue Archives and Supporting Human Research: Challenges and Solutions. Archives of Pathology and Laboratory Medicine, 2011, 135, 347-353.	1.2	13
105	High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta Neuropathologica, 2022, 143, 403-414.	3.9	13
106	Radiation-Induced Cavernous Malformations After Single-Fraction Meningioma Radiosurgery. Operative Neurosurgery, 2018, 15, 207-212.	0.4	12
107	Telomere alterations in neurofibromatosis type 1-associated solid tumors. Acta Neuropathologica Communications, 2019, 7, 139.	2.4	12
108	TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma?. Neuro-Oncology, 2021, 23, 865-866.	0.6	12

#	Article	IF	CITATIONS
109	Expanding the spectrum of EWSR1â€PATZ1 rearranged CNS tumors: An infantile case with leptomeningeal dissemination. Brain Pathology, 2021, 31, e12934.	2.1	11
110	The Third Eye Sees Double: Cohort Study of Clinical Presentation, Histology, Surgical Approaches, and Ophthalmic Outcomes in Pineal Region Germ Cell Tumors. World Neurosurgery, 2021, 150, e482-e490.	0.7	11
111	N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology, 2007, 25, 2004-2004.	0.8	11
112	Adenoid Cystic Carcinoma Metastatic to the Pituitary: A Case Report and Discussion of Potential Diagnostic Value of Magnetic Resonance Elastography in Pituitary Tumors. World Neurosurgery, 2016, 91, 669.e11-669.e14.	0.7	10
113	Glioblastoma of the cerebellopontine angle and internal auditory canal mimicking a peripheral nerve sheath tumor: case report. Journal of Neurosurgery, 2019, 131, 1835-1839.	0.9	10
114	DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival. Acta Neuropathologica, 2022, 144, 155-157.	3.9	10
115	Intracranial cellular schwannomas: a clinicopathological study of 20 cases. Histopathology, 2020, 76, 275-282.	1.6	9
116	Intracranial angiomatoid fibrous histiocytoma with rhabdoid features: a mimic of rhabdoid meningioma. Brain Tumor Pathology, 2021, 38, 138-144.	1.1	9
117	SeekFusion - A Clinically Validated Fusion Transcript Detection Pipeline for PCR-Based Next-Generation Sequencing of RNA. Frontiers in Genetics, 2021, 12, 739054.	1.1	9
118	Roles of Tumor Markers in Central Nervous System Germ Cell Tumors Revisited with Histopathology-Proven Cases in a Large International Cohort. Cancers, 2022, 14, 979.	1.7	9
119	Synchronous Tumors of the Cerebellopontine Angle. World Neurosurgery, 2017, 98, 632-643.	0.7	8
120	Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype―IDH-mutant infiltrating gliomas. Acta Neuropathologica, 2020, 139, 1105-1107.	3.9	8
121	Primary papillary epithelial tumour of the sella: expanding the spectrum of TTFâ€lâ€positive sellar lesions. Neuropathology and Applied Neurobiology, 2020, 46, 493-505.	1.8	8
122	Glioneuronal Heterotopia Presenting as Cerebellopontine Angle Tumor of Cranial NerveÂVIII. World Neurosurgery, 2018, 114, 289-292.	0.7	7
123	A Pediatric Intra-Axial Malignant SMARCB1-Deficient Desmoplastic Tumor Arising in Meningioangiomatosis. Journal of Neuropathology and Experimental Neurology, 2018, 77, 883-889.	0.9	7
124	Granular cell astrocytoma: an aggressive <scp>IDH</scp> â€wildtype diffuse glioma with molecular genetic features of primary glioblastoma. Brain Pathology, 2019, 29, 193-204.	2.1	7
125	Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin—a novel tumor checkpoint controller targeting microtubules. Neuro-Oncology, 2022, 24, 384-395.	0.6	7
126	Genetic and epigenetic characterization of posterior pituitary tumors. Acta Neuropathologica, 2021, 142, 1025-1043.	3.9	7

#	Article	IF	CITATIONS
127	Longâ€ŧerm oncologic outcomes in esthesioneuroblastoma: An institutional experience of 143 patients. International Forum of Allergy and Rhinology, 2022, 12, 1457-1467.	1.5	7
128	Recurrent ACVR1 mutations in posterior fossa ependymoma. Acta Neuropathologica, 2022, 144, 373-376.	3.9	7
129	Association of amyloid angiopathy with microbleeds in logopenic progressive aphasia: an imagingâ€pathology study. European Journal of Neurology, 2021, 28, 670-675.	1.7	6
130	TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants. Clinical Neurology and Neurosurgery, 2020, 196, 106059.	0.6	5
131	The Alliance AMBUSH Trial: Rationale and Design. Cancers, 2022, 14, 414.	1.7	5
132	Periventricular white matter immunoglobulin lambda light chain deposition disease diagnosed by proteomic analysis. Acta Neuropathologica, 2012, 124, 293-295.	3.9	4
133	Rhabdoid-like meningioma with inclusions consisting of accumulations of complex interdigitating cell processes rather than intermediate filaments. Acta Neuropathologica, 2014, 127, 937-939.	3.9	4
134	Giant Cell Ependymoma of Lateral Ventricle: Case Report, Literature Review, and Analysis of Prognostic Factors and Genetic Profile. World Neurosurgery, 2017, 108, 997.e9-997.e14.	0.7	4
135	Trigeminal Amyloidoma: A Report of Two Cases and Review of the Literature. Journal of Neurological Surgery, Part B: Skull Base, 2020, 81, 620-626.	0.4	4
136	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. Neurocase, 2021, 27, 212-222.	0.2	4
137	A Comprehensive Study of Spindle Cell Oncocytoma of the Pituitary Gland: Series of 6 Cases and Meta-Analysis of 85 Cases. World Neurosurgery, 2021, 149, e197-e216.	0.7	4
138	Sarcomatous Meningioma: Diagnostic Pitfalls and the Utility of Molecular Testing. Journal of Neuropathology and Experimental Neurology, 2021, 80, 764-768.	0.9	4
139	Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. Journal of Clinical Oncology, 2004, 22, 1508-1508.	0.8	4
140	Brachial plexus lipomatosis with perineurial pseudoonion bulb formation: Result of a mosaic PIK3CA mutation in the paraâ€axial mesoderm state. Brain Pathology, 2022, 32, e13057.	2.1	4
141	Case-based review: primary central nervous system lymphoma. Neuro-Oncology Practice, 2017, 4, 46-59.	1.0	3
142	Can Intraneural Perineuriomas Occur Intradurally? An Anatomic Perspective. Neurosurgery, 2017, 80, 226-234.	0.6	3
143	Lowâ€grade fibromyxoid sarcoma arising within the median nerve. Neuropathology, 2018, 38, 309-314.	0.7	3
144	A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum?. BMJ Case Reports, 2018, 2018, bcr-2018-225318.	0.2	3

#	Article	IF	CITATIONS
145	Histopathology and prognosis of germ cell tumors metastatic to brain: cohort study. Journal of Neuro-Oncology, 2021, 154, 121-130.	1.4	3
146	Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism. Acta Neuropathologica, 2017, 134, 317-319.	3.9	3
147	SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. American Journal of Surgical Pathology, 2022, 46, 1277-1283.	2.1	3
148	Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors. Annals of Diagnostic Pathology, 2022, 59, 151967.	0.6	3
149	Solitary Metastasis to the Facial/Vestibulocochlear Nerve Complex: Case Report andÂReview of the Literature. World Neurosurgery, 2015, 84, 1178.e15-1178.e18.	0.7	2
150	Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. Journal of Clinical Oncology, 2004, 22, 1508-1508.	0.8	2
151	Review of WHO 2016 Changes to Classification of Gliomas; Incorporation of Molecular Markers. , 2020, , 127-138.		2
152	Optic Nerve Choristoma Mimicking a Neurenteric Cyst. American Journal of Neuroradiology, 2021, 42, 228-232.	1.2	2
153	Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-Oncology Advances, 2022, 4, .	0.4	2
154	Ultrastructural Morphometric Analysis of Human Sural Nerve Biopsies. Diabetic Medicine, 1996, 13, 675-676.	1.2	1
155	Intravascular mucinosis: a rare cause of cerebral infarction. Acta Neuropathologica, 2011, 121, 785-788.	3.9	1
156	Anaplastic Ependymoma and Posterior Fossa Grouping in a Patient With H3K27ME3 Loss of Expression but Chromosomal Imbalance. Advances in Radiation Oncology, 2019, 4, 466-472.	0.6	1
157	Experimental gliomas in mice using the Sleeping Beauty (SB) transposon system: neuropathologic aspects. FASEB Journal, 2008, 22, 172.4.	0.2	1
158	Delaying Postoperative Radiotherapy in Low-Grade Esthesioneuroblastoma: Is It Worth the Wait?. Journal of Neurological Surgery, Part B: Skull Base, 2021, 82, e166-e171.	0.4	1
159	Reply: A new case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) with initial normal magnetic resonance imaging. Brain, 2011, 134, e183-e183.	3.7	Ο
160	Bizarre Semiology and Medically Intractable Seizures. Seminars in Pediatric Neurology, 2014, 21, 154-159.	1.0	0
161	24‥earâ€Old Woman with Recent Onset Back Pain. Brain Pathology, 2015, 25, 786-787.	2.1	0
162	The dangers of the "Head Down―position in patients with untreated pituitary macroadenomas: case series and review of literature. Pituitary, 2018, 21, 231-237.	1.6	0

#	Article	IF	CITATIONS
163	Non-canonical IDH Mutation Frequency in IDH1-R132H-Negative Glioblastoma Patients Older Than 54 Years. Journal of Neuropathology and Experimental Neurology, 2021, 80, 804-806.	0.9	0
164	Phase II trial of irinotecan (CPT-11) and radiation followed by irinotecan and BCNU in glioblastoma patients (pts). Journal of Clinical Oncology, 2006, 24, 1562-1562.	0.8	0
165	Retrospective survival comparison of patients with cerebral versus cerebellar glioblastomas. FASEB Journal, 2008, 22, 706.7.	0.2	0
166	Gliomas of childhood. Pathologica, 2003, 95, 237.	1.3	0
167	Diffuse Large B-Cell Lymphoma of Peripheral Nerve with Distinctive Pathological Features Resembling Primary CNS Lymphoma. Journal of Neuropathology and Experimental Neurology, 2021, , .	0.9	0
168	ATRT-08. SMARCB1- and SMARCA4-deficient malignant brain tumors with complex copy number alterations and <i>TP53</i> mutations may represent the first clinical manifestation of Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i4-i4.	0.6	0